Titan Partners, a division of American Capital Partners, today announced the launch of its Equity Research Division with the appointment of Boris Peaker, Ph.D., CFA, as managing director and senior equity research analyst. Dr. Peaker brings 17 years of experience in healthcare equity research and will lead the firm’s research initiatives in the healthcare sector, focusing on biotechnology. “The launch of our research platform, spearheaded by Dr. Peaker, marks an important milestone in Titan’s growth,” said Jason Sands, co-founder and partner at Titan. “Our mission has always been to build a business around fundamentally strong and scientifically compelling stories. Dr. Peaker’s experience and reputation align perfectly with this objective.”
To view the full press release, visit https://ibn.fm/9yZOs
About Titan Partners Group
Titan Partners Group, a division of American Capital Partners, is a boutique investment bank specializing in tailored solutions for emerging growth companies and their investors. Headquartered in New York City, Titan Partners offers a full suite of capabilities, including investment banking, capital markets advisory, and research. Committed to setting the standard for securities transactions in the middle market, Titan Partners combines expertise, trust, and a forward-thinking approach to deliver results and help corporate clients achieve their strategic goals. For more information, visit TitanPartnersGrp.com.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
